DUBLIN--(BUSINESS WIRE)--The "Artificial Pancreas Device System Market to 2025 - Global Analysis and Forecasts by Type (Control to Range, Control to Target and Threshold Suspended Device Systems); and Geography" report has been added to ResearchAndMarkets.com's offering.
The global artificial pancreas device systems market is expected to reach US$ 2,168.1 million in 2025 from US$ 481.8 million in 2017. The market is estimated to grow with a CAGR of 20.9% from 2016-2025.
Driving factors such as, growing prevalence of diabetes, developments by major players, rise in demand for computerized systems for glycemic control are expected to boost the market growth over the years. In addition, increasing medical tourism in emerging nations are likely to have a positive impact on the growth of the global artificial pancreas device systems market in the coming years.
However, availability of alternatives for artificial pancreas device systems and high cost associated with these systems are likely to negatively affect the market growth in the coming years. On the other hand, use of pancreas cell implant is expected to be one of the prevalent trends in the market.
The advanced technology developed for the diabetes treatment is the pancreas cell implant developed in November 2017, by a California company, Encellin. The company aims to eradicate insulin injections for diabetic patients with an insulin-producing implant containing live cells. The device is in preclinical trials and the company is organizing for clinical trials.
The concept of packaging cells in semipermeable membranes could have other medical uses as well. This promising technology will help in the removal of the diabetes related problems and are expected to be prevalent future trend in artificial pancreas device systems market.
Global artificial pancreas device systems market, based on the type was segmented into control to range, control to target and threshold device systems. In 2017, the threshold suspended device systems segment held a largest market share of 71.5% of the artificial pancreas device systems market, by type.
The threshold suspended device systems is the largest segment among the type segment in the artificial pancreas devices system market in 2017 and is also anticipated to hold the largest market in the year 2025. However, the control to target segment is the fastest growing segment and is accounted to grow at the CAGR of 21.4% over the forecast years.
Topics Covered
1. Introduction
2. Global Artificial Pancreas Device Systems Market - Key Takeaways
3. Global Artificial Pancreas Device Systems Market - Market Landscape
3.1 Overview
3.2 Market Segmentation
3.3 PEST Analysis
4. Global Artificial Pancreas Device Systems Market - Key Market Dynamics
4.1 Key Market Drivers
4.2 Key Market Restraints
4.3 Key Market Opportunities
4.4 Future Trends
4.5 Impact Analysis
5. Artificial Pancreas Device Systems Market - Global Analysis
5.1 Global Artificial Pancreas Device Systems Market Revenue Forecasts and Analysis
5.2 Global Artificial Pancreas Device Systems Market, by Geography - Forecasts and Analysis
5.3 Prominent Players in the Market
5.4 Expert Opinions
6. Global Artificial Pancreas Devices Systems Analysis - by Type
7. North America Artificial Pancreas Device Systems Market Revenue and Forecasts to 2025
8. Europe Artificial Pancreas Device Systems Market Revenue and Forecasts to 2025
9. Asia Pacific Artificial Pancreas Device Systems Market Revenue and Forecasts to 2025
10. Middle East and Africa Artificial Pancreas Device Systems Market Revenue and Forecasts to 2025
11. South and Central America Artificial Pancreas Device Systems Market Revenue and Forecasts to 2025
12. Artificial Pancreas Device Systems Market - Industry Landscape
12.1 Overview
12.2 Growth Strategies In the Artificial Pancreas Device Systems Market, 2016-2018
12.3 Organic Growth Strategies
12.4 Inorganic Growth Strategies
13. Artificial Pancreas Device Systems Market - Key Company Profiles
13.1 Defymed
13.2 Typezero Technologies Inc.
13.3 Insulet Corporation
13.4 Bigfoot Biomedical Inc.
13.5 Medtronic
13.6 Dexcom Inc.
13.7 Admetsys
13.8 Beta Bionics
13.9 Cellnovo
13.10 Tandem Diabetes Care Inc.
For more information about this report visit https://www.researchandmarkets.com/research/s6hnm6/2_1_billion?w=4
